Background
The association between preoperative use of infliximab and postoperative complications in patients with inflammatory bowel disease (IBD) is a subject of continued debate. Results from studies examining an association between the timing of last preoperative dose of infliximab and postoperative complications remain inconsistent.
Aims
To assess if timing of last dose of infliximab prior to surgery affects the rate of postoperative complications in patients with Crohn’s disease or ulcerative colitis
Methods
Retrospective chart review of IBD patients who have undergone surgery while receiving therapy with infliximab was conducted. Forty seven patients were included in the analysis.
Results
No significant association was found between timing of infliximab and the rate of postoperative complications. Age, gender, disease type, steroid use, preoperative status, surgery type or surgeon type were not associated with increased rate of postoperative complications.
Conclusion
Timing of last dose of infliximab does not affect the rate of postoperative complications in patients with Crohn’s disease or ulcerative colitis.
We report a case of ulcerative colitis developing in a colonic transposition used for creation of a neovagina in a patient with congenital Muellerian agenesis. The onset of vaginal disease preceded the development of colonic disease and was more resistant to treatment compared to the colon disease failing multiple escalating therapies. Patient is currently in remission on biologic therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.